CytoDyn (OTC: CYDY) Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH
VANCOUVER, Washington, Jun 11, 2020 — Preclinical results demonstrated leronlimab effectively inhibited fatty liver development VANCOUVER, Washington, June 11, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), […]
